RARA and acute promyelocytic leukemia: The last two issues allow to overcome the RT-qPCR limitations in monitoring several fusion transcripts, such as both canonical and atypical BCR–ABL1 breakpoints in CML patients [16] and PML/RARA in acute promyelocytic leukemia (APL) [17], guiding the therapeutic strategy.